Related Experiment Video

Updated: Aug 7, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K

Statin Treatment Is Associated with Alterations in the Platelet Lipidome

Tobias Harm1, Moritz Frey1, Kristina Dittrich2

  • 1Department of Cardiology and Angiology, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.

Thrombosis and Haemostasis
|March 10, 2023
PubMed

Insights

Statin treatment alters the platelet lipidome in coronary artery disease (CAD) patients, upregulating triglycerides and downregulating glycerophospholipids. This lipid profile shift may influence cardiovascular event risk.

Area of Science:

  • Cardiovascular Medicine
  • Lipidomics
  • Platelet Biology

Background:

  • Platelets are central to coronary artery disease (CAD) pathophysiology, with hyperreactivity increasing cardiovascular event risk.
  • Acute coronary syndrome (ACS) involves significant platelet lipidome changes, impacting platelet responsiveness.
  • Statins are vital for CAD management, influencing lipid metabolism.

Purpose of the Study:

  • To investigate the platelet lipidome in CAD patients using untargeted lipidomics.
  • To identify differences in the platelet lipidome between statin-treated and statin-naïve patients.

Main Methods:

  • Characterization of the platelet lipidome in 105 CAD patients.
  • Utilized untargeted lipidomics via liquid chromatography-mass spectrometry.

Main Results:

  • 41 lipids were upregulated and 6 downregulated in statin-treated versus naïve CAD patients.
  • Upregulated lipids included triglycerides, cholesteryl esters, palmitic acid, and oxidized phospholipids.
  • Downregulated lipids were primarily glycerophospholipids, with a more pronounced statin effect in ACS patients and a dose-dependent influence.

Conclusions:

  • Statin treatment significantly alters the platelet lipidome in CAD patients.
  • Upregulated triglycerides and downregulated glycerophospholipids may influence CAD pathophysiology.
  • Findings contribute to understanding how statins modulate the lipid phenotype in CAD.
Abstract

More Related Videos

LC-MS Analysis of Human Platelets as a Platform for Studying Mitochondrial Metabolism06:04

LC-MS Analysis of Human Platelets as a Platform for Studying Mitochondrial Metabolism

Published on: April 4, 2016

11.3K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.5K

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
726
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
575
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
16
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
19
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
15
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
237